AB
EPZM

Amalgamated Bank’s Epizyme, Inc EPZM Stock Holding History

Amalgamated Bank’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26,516
Closed -$30K – 3318
2022
Q1 		$30K Buy
26,516
+10,458
+65% +$17K ﹤0.01% 2688
2021
Q4 		$40K Sell
16,058
-230
-1% -$904 ﹤0.01% 2120
2021
Q3 		$83K Sell
16,288
-667
-4% -$4.05K ﹤0.01% 2097
2021
Q2 		$141K Buy
16,955
+6,135
+57% +$51.7K ﹤0.01% 2074
2021
Q1 		$94K Sell
10,820
-820
-7% -$8.48K ﹤0.01% 1557
2020
Q4 		$126K Buy
11,640
+66
+0.6% +$814 ﹤0.01% 1513
2020
Q3 		$138K Sell
11,574
-269
-2% -$3.6K 0.01% 1367
2020
Q2 		$190K Sell
11,843
-1,671
-12% -$29.2K 0.01% 1311
2020
Q1 		$210K Sell
13,514
-806
-6% -$17.3K 0.01% 1344
2019
Q4 		$352K Buy
14,320
+1,174
+9% +$17.4K 0.01% 1313
2019
Q3 		$136K Sell
13,146
-94
-0.7% -$1.19K ﹤0.01% 1616
2019
Q2 		$166K Buy
+13,240
New +$170K ﹤0.01% 1626

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Amalgamated Bank's EPZM Position: Q2 2022 in Review

Amalgamated Bank sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 26,516 shares — an estimated $30K sold.

Amalgamated Bank first reported a position in EPZM in Q2 2019 and held it in 12 quarters. The position peaked at $352K in Q4 2019. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • Amalgamated Bank reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • Amalgamated Bank sold 26,516 Epizyme, Inc shares in Q2 2022, an estimated $30K.
  • Amalgamated Bank first reported a position in Epizyme, Inc in Q2 2019 and held it in 12 quarters.
  • Amalgamated Bank's Epizyme, Inc position peaked at $352K in Q4 2019.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.